PHARMACOGENETIC ANALYSIS OF THE INTERACTION OF THE LOW-MOLECULAR WEIGHT BDNF MIMETIC DIPEPTIDE GSB-106 WITH TRK RECEPTORS

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Using TrkA or TrkB receptor gene knockout HT-22 cells showed the selectivity of the interaction of the low molecular weight dipeptide BDNF mimetic GSB-106 (hexamethylenediamide bis(N-monosuccinyl-L-seryl-L-lysine)) with TrkB receptors.

About the authors

T. A. Antipova

Federal State Budgetary Institution “Research Zakusov Institue of Pharmacology”

Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

I. O. Logvinov

Federal State Budgetary Institution “Research Zakusov Institue of Pharmacology”

Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

I. E. Deyev

State Scientific Center Federal State Budgetary Institution of Science “Shemyakin–Ovchinnikov Institute of bioorganic chemistry, Russian Academy of Sciences”

Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

P. Yu. Povarnina

Federal State Budgetary Institution “Research Zakusov Institue of Pharmacology”

Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

Yu. V. Vakhitova

Federal State Budgetary Institution “Research Zakusov Institue of Pharmacology”

Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

T. A. Gudasheva

Federal State Budgetary Institution “Research Zakusov Institue of Pharmacology”

Author for correspondence.
Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

S. B. Seredenin

Federal State Budgetary Institution “Research Zakusov Institue of Pharmacology”

Email: tata-sosnovka@mail.ru
Russian Federation, Moscow

References

  1. Gliwińska A., Czubilińska-Łada J., Więckiewicz G., et al. The role of brain-derived neurotrophic factor (BDNF) in diagnosis and treatment of epilepsy, depression, schizophrenia, anorexia nervosa and Alzheimer’s disease as highly drug-resistant diseases: a narrative review // Brain Sciences. 2023. V. 13. № 2. P. 163.
  2. Alfonsetti M., d’Angelo M., Castelli V. Neurotrophic factor-based pharmacological approaches in neurological disorders // Neural Regen Res. 2023. V. 18. № 6. P. 1220–1228.
  3. Colucci-D’Amato L., Speranza L., Volpicelli F. Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer // Int J Mol Sci. 2020. V. 21. № 20. P. 7777.
  4. Camuso S., Canterini S. Brain-derived neurotrophic factor in main neurodegenerative diseases // Neural Regen Res. 2023. V. 18. № 3. P. 554–555.
  5. Cavaleri D., Moretti F., Bartoccetti A., et al. The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: insight from meta-analyses // Neurosci Biobehav Rev. 2023. P. 105159.
  6. Scharfman H.E., Goodman J.H., Sollas A.L., et al. Spontaneous limbic seizures after intrahippocampal infusion of brain-derived neurotrophic factor // Exp Neurol. 2002. V. 174. № 2. P. 201–214.
  7. Pelleymounter M.A., Cullen M.J., Wellman C.L. Characteristics of BDNF-induced weight loss // Exp Neurol. 1995. V. 131. № 2. P. 229–238.
  8. Massa S.M., Yang T., Xie Y., et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents // J Clin Invest. 2010. V. 120. № 5. P. 1774–1785.
  9. Longo F.M., Massa S.M. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease // Nat Rev Drug Discov. 2013. V. 12. № 7. P. 507–525.
  10. Fletcher J.L., Dill L.K., Wood R.J., et al. Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and preserves myelin integrity in a mouse model of pediatric traumatic brain injury // Exp Neurol. 2021. V. 339. P. 113652.
  11. Emili M., Guidi S., Uguagliati B., et al. Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders // Crit Rev Food Sci Nutr. 2022. V. 62. № 1. P. 13–50.
  12. Wang S., Yao H., Xu Y., et al. Therapeutic potential of a TrkB agonistic antibody for Alzheimer’s disease // Theranostics. 2020. V. 10. № 15. P. 6854–6874.
  13. Гудашева Т.А., Тарасюк А.В., Помогайбо С.В., и др. Дизайн и синтез дипептидных миметиков мозгового нейротрофического фактора // Биоорган. химия. 2012. Т. 38. № 3. С. 280–290.
  14. Гудашева Т.А., Логвинов И.О., Николаев С.В., и др. Дипептидные миметики отдельных петель NGF и BDNF активируют PLC-γ1 // Доклады Российской академии наук. Науки о жизни. 2020. Т. 494. № 1. С. 486–490.
  15. Жердев В.П., Колыванов Г.Б., Литвин А.А., и др. Фармакокинетика дипептидного миметика BDNF ГСБ-106 у крыс // Фармакокинетика и фармакодинамика. 2019. № 1. С. 37–43.
  16. Gudasheva T.A., Tallerova A.V., Mezhlumyan A.G., et al. Low-molecular weight BDNF mimetic, dimeric dipeptide GSB-106, reverses depressive symptoms in mouse chronic social defeat stress // Biomolecules. 2021. V. 11. № 2. P. 252.
  17. Vakhitova Y.V., Kalinina T.S., Zainullina L.F., et al. Analysis of antidepressant-like effects and action mechanisms of GSB-106, a small molecule, affecting the TrkB signaling // Int J Mol Sci. 2021. V. 22. № 24. P. 13381.
  18. Антипова Т.А., Деев И.Е., Гудашева Т.А., и др. Доказательство селективности взаимодействия дипептидного миметика фактора роста нервов ГК-2 с TrkA-рецептором с использованием нокаутных по генам trka и trkb клеток линии НТ-22 // Химико-Фармацевтический Журнал. 2022. Т. 56. № 12. С. 18–22.
  19. Ran F., Hsu P., Wright J. et al. Genome engineering using the CRISPR-Cas9 system // Nat Protoc. 2013. № 8. P. 2281–2308.
  20. Jackson G.R., Werrbach-Perez K., Ezell E.L., et al. Nerve growth factor effects on pyridine nucleotides after oxidant injury of rat pheochromocytoma cells // Brain Res. 1992. V. 592. № 1–2. P. 239–248.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2.

Download (157KB)
Indexing metadata
3.

Download (196KB)
Indexing metadata
4.

Download (181KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies